Group items tagged

Androgen deprivation therapy in men has been shown to worsen insulin resistance and precipitate type II Diabetes as well as stimulate weight gain.  This suggests a cause effect relationship between Testosterone and insulin sensitivity.  Other studies have pointed to a reciprocal decline in Testosterone due to hyperglycemia--both acute and chronic.   Androgen deprivation has a significant long list of cardiovascular risks and this should be discussed with the patient.

Androgen deprivation therapy is associated with increased diabetes, metabolic syndrome, insulin resistance, and cardiovascular mortality.  The longer the duration of therapy, the more the progression of metabolic dysfunction.  This process seems similar to chemotherapy i.e. secondary cancer due to chemotherapy.  The treatment of one disease, prostate cancer in this case, leads to an increase in the risk of the #1 killer in men--logic seems severely flawed there.

Androgen deprivation therapy was found to decrease lean muscle mass and increase abdominal adipose tissue, not visceral.  Significant change in body composition in men depleted of androgens in androgen deprivation therapy.

animal study finds that Testosterone therapy is cardioprotective in a preventative mode and with myocardial injury.  Normalization of Testosterone in these animals with low T reduced infant injury size and improved heart function.  

another awesome article dealing with hormone metabolites. Physicians that don't understand metabolites and receptors may be doing more harm than good.   One of the mainstays of the treatment of metastatic prostate disease is androgen deprivation therapy.  This article requires a reassessment of this due to the DHT metabolite 3-beta androstanediol.  This metabolite is produced from DHT production via the enzyme 3beta HSD.  This metabolite binds to ER beta, an estrogen receptor, and inhibits proliferation, migration, promotes adhesion (limits spreading), and stimulates apoptosis.  This is contrast to 3-alpha androstanediol.  Androgen deprivation therapy will decrease 3-beta androstanediol.  This is the likely reason for the increased aggressive prostate cancer found in those men using 5 alpha reductase inhibitors.

this study found no increase in inflammatory cytokines in those men on androgen deprivation therapy for prostate cancer.  The question, is they evaluated testosterone in the serum, so did they really see a decrease in androgens or just a decrease in the transport of androgens.  Saliva would have detected a true androgen deficient state.

Androgen deprivation therapy reduces Telomerase activity in androgen dependent prostate cancer cell lines.  Conversely, Testosterone increases Telomerase activity.  In these cell lines Telomerase activity is positively associated with prostate cancer.

No benefit from Primary androgen deprivation therapy in localized prostate cancer.

androgen deprivation therapy associated with increased type II diabetes, myocardial infarction and CAD.

Interesting concept on Androgen deprivation therapy.  ADT has significant negative metabolic effects in men.  Here Intermittent ADT is evaluated and found to be questionable in its outcome.

Androgen deprivation therapy increases fatal heart attack risk in those with prostate cancer.  Also of note, the ADT therapy group did not provide a survival benefit over that of radiation alone.

sleep deprivations leads to reduced glutathione production (in rat study) and increased oxidative stress in the brain.  

Androgen Deprivation Therapy, ADT,  is associated with increased cardiovascular mortality in men with pre-existing CVD.  This has also been shown to be the case with IR, Diabetes, weight gain...What man 40+ with prostate cancer doesn't have some degree of CVD??

Androgen deprivation Therapy is full of risks--of particular is cardiovascular disease, obesity, fatigue, diabetes, insulin resistance...

Androgen deprivation therapy appears to increase Alzheimer's disease risk.  In this study, the men on ADT the longest was found to be associated with increased diagnosis of Alzheimer's disease.

new risk potential for Androgen Deprivation Therapy (ADT) for men with prostate cancer--increased Alzheimer's disease risk.

Serum Testosterone levels and intra-prostatic Testosterone levels in men are very different in men with androgen deprivation therapy.  Though there is a 94% serum reduction, intra-prostatic Testosterone levels remain 20-30% higher.  

This article discusses the failure of androgen deprivation therapy and prostate cancer.  This failure is quite common.  The authors point to alpha-DHT as the primary mechanism through AR stimulation.  However, we know that DHT metabolites also stimulate estrogen receptors.

Night shift work and sleep deprivation associated with increased inflammatory markers: IL-6, TNF-alpha, and CRP.

Androgen deprivation therapy resulted in an 11% increase in fat mass and just under 4% decrease in lean muscle mass in men.